このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Sanofi 将来の成長

Future 基準チェック /26

Sanofi利益と収益がそれぞれ年間16.9%と5.2%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に14% 17.4%なると予測されています。

主要情報

16.9%

収益成長率

17.4%

EPS成長率

Pharmaceuticals 収益成長	16.1%
収益成長率	5.2%
将来の株主資本利益率	14.0%
アナリストカバレッジ	Good
最終更新日	13 May 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

ENXTPA:SANNV - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	52,775	9,646	10,260	N/A	14
12/31/2025	49,936	8,689	9,235	N/A	16
12/31/2024	46,247	7,066	7,389	N/A	13
3/31/2024	46,288	4,538	N/A	N/A	N/A
12/31/2023	46,033	5,400	7,234	10,258	N/A
9/30/2023	45,699	9,066	N/A	N/A	N/A
6/30/2023	46,045	8,617	8,107	10,264	N/A
3/31/2023	46,199	8,357	N/A	N/A	N/A
12/31/2022	45,389	8,371	8,325	10,526	N/A
9/30/2022	44,348	6,409	N/A	N/A	N/A
6/30/2022	42,039	6,643	7,594	9,620	N/A
3/31/2022	40,342	6,666	N/A	N/A	N/A
12/31/2021	39,175	6,223	8,479	10,522	N/A
9/30/2021	38,496	6,174	N/A	N/A	N/A
6/30/2021	37,546	5,777	5,827	8,219	N/A
3/31/2021	36,939	12,197	N/A	N/A	N/A
12/31/2020	37,369	12,294	5,335	7,418	N/A
9/30/2020	37,650	11,224	N/A	N/A	N/A
6/30/2020	37,692	11,138	6,834	8,491	N/A
3/31/2020	38,234	3,453	N/A	N/A	N/A
12/31/2019	37,631	2,855	5,928	7,715	N/A
9/30/2019	36,940	3,179	N/A	N/A	N/A
6/30/2019	36,763	3,591	4,958	6,953	N/A
3/31/2019	36,264	4,439	N/A	N/A	N/A
12/31/2018	35,677	4,319	3,570	5,547	N/A
9/30/2018	35,316	4,041	N/A	N/A	N/A
6/30/2018	34,985	3,243	4,815	6,596	N/A
3/31/2018	35,428	3,539	N/A	N/A	N/A
12/31/2017	36,221	3,773	N/A	7,379	N/A
9/30/2017	36,400	4,593	N/A	N/A	N/A
6/30/2017	36,315	4,744	N/A	8,133	N/A
3/31/2017	35,677	4,682	N/A	N/A	N/A
12/31/2016	34,696	4,395	N/A	7,838	N/A
9/30/2016	34,349	4,195	N/A	N/A	N/A
6/30/2016	34,115	4,154	N/A	8,122	N/A
3/31/2016	34,569	4,440	N/A	N/A	N/A
12/31/2015	34,861	4,411	N/A	8,920	N/A
9/30/2015	37,201	5,292	N/A	N/A	N/A
6/30/2015	32,910	4,628	N/A	8,561	N/A
3/31/2015	35,074	4,329	N/A	N/A	N/A
12/31/2014	31,999	4,273	N/A	7,690	N/A
9/30/2014	33,484	4,112	N/A	N/A	N/A
6/30/2014	33,134	4,140	N/A	7,463	N/A
3/31/2014	33,074	3,812	N/A	N/A	N/A
12/31/2013	31,291	3,639	N/A	6,954	N/A
9/30/2013	33,424	3,127	N/A	N/A	N/A
6/30/2013	34,146	3,364	N/A	5,869	N/A

アナリストによる今後の成長予測

収入対貯蓄率: SANNVの予測収益成長率 (年間16.9% ) は貯蓄率 ( 1.1% ) を上回っています。

収益対市場: SANNVの収益 ( 16.9% ) はFrench市場 ( 11.1% ) よりも速いペースで成長すると予測されています。

高成長収益: SANNVの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: SANNVの収益 ( 5.2% ) French市場 ( 5.8% ) よりも低い成長が予測されています。

高い収益成長: SANNVの収益 ( 5.2% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: SANNVの自己資本利益率は、3年後には低くなると予測されています ( 14 %)。

Sanofi 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Sanofi Reiterates Earnings Guidance for the Year 2023

Recent updates

Sanofi to Present New Data from its Hemophilia Portfolio at the 32nd Congress of the International Society on Thrombosis and Haemostasis

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Sarclisa Accepts for FDA Priority Review for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Sanofi Announces Board and Committee Appointments

Sanofi Announces Board and Committee Appointments

Sanofi Announces Quebec's INESSS Recommends BEYFORTUS® for Prevention of RSV for All Infants 8 Months of Age and Younger

Sanofi Announces Launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups

Sanofi Announces Phase 2b Results for Amlitelimab Support Potential for Best-In-Class Maintenance of Response in Atopic Dermatitis

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Sanofi Reports Impairment of Intangible Assets for the Fourth Quarter Ended December 31, 2023

Sanofi Announces CFO Changes, Effective April 1, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Sanofi to Report Q3, 2024 Results on Oct 25, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab)

Sanofi Appoints Brian Foard as Head of Specialty Care Global Business Unit and Member of Executive Committee

Sanofi to Report Q4, 2023 Results on Feb 01, 2024

Sanofi Announces Dupixent Significantly Reduced (34%) Exacerbations, Confirming Positive Published Results from the Landmark Phase 3 Boreas Trial

Sanofi to Report Q2, 2024 Results on Jul 25, 2024

Sanofi Reiterates Earnings Guidance for the Year 2023

Sanofi Announces Positive Results from a Phase 3 Trial Demonstrated the Efficacy and Safety Profile of Dupixent (Dupilumab) for Up to One Year (52 Weeks) in Children Aged 1 to 11 Years

Regeneron Pharmaceuticals, Inc. and Sanofi Provide Update on Dupixent®? (Dupilumab) sBLA for Chronic Spontaneous Urticaria

Sanofi Delivers First Medicines from Global Health Unit's Impact Brand Portfolio

Sanofi Reportedly Explores Potential Acquisition of Mirati Therapeutics

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘